Claims for Patent: 8,445,532

Summary for Patent: 8,445,532

Title:	Use of phthalide derivatives
Abstract:	Phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent are described. The phthalide derivatives can enhance the sensitivity of drug-resistance tumor cells against chemotherapy and decrease the drug-resistance of tumor cells 5-30 folder and enhance notably several chemotherapy agents-induced apoptosis of tumor cells.
Inventor(s):	Chen; Fei (Shanghai, CN), Wang; Tao (Shanghai, CN)
Assignee:
Application Number:	12/088,778
Patent Claims:	1. A method of treating a tumor having resistance to an anti-cancer drug in a subject, wherein the tumor exhibits either (1) overexpression of at least one selected from the group consisting of P-gp and Bcl-2, or (2) over-activity of glyoxalase I, the method comprising: administering to the subject, the anti-cancer drug and a therapeutically effective amount of at least one phthalide compound selected from the group consisting of ##STR00016## ##STR00017## ##STR00018## wherein the amount is an amount effective for inhibiting either (1) overexpression of at least one selected from the group consisting of P-gp and Bcl-2, or (2) over-activity of glyoxalase I in the subject. 2. The method of claim 1, further comprising administering at least one anti-tumor drug selected from the group consisting of: doxorubicin; Vincristine; paclitaxel; Cisplatin; Actinomycin; Bleomycin; Busulfan; Capecitabine; Carboplatin; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etop1; Vepeside; Etoposide; Fludarabine; Fluorouracil; Gemcitabine; Trastuzumab; Hydroxycarbamide; Idarubicin; Ifosfamide; Irinotecan; Lomustine; Melphalan; Mercaptopurine; Methotrexate; Mitomycin; Mitoxantrone; Dihydroxyanthraquinone; Oxaliplatin; Procarbazine; Methylhydrazine; rituximab; Steroid; Streptozocin; Docetaxel; Thioguanine; Thiotepa; Ledertepa; Tespamin; Raltitrexed; Topotecan; Treosulfan; Uracil; Vinblastine; Vinca alkaloid; Vindesine; Vinorelbine; Hydroxycamptothecin; and mixtures thereof. 3. The method of claim 2, wherein said at least one anti-tumor drug is used to treat tumors selected from the group consisting of: non-small cell lung cancer, prostate cancer, intestinal cancer, hepatocarcinoma, leukaemia, myeloma, lymphoma, mammary cancer, ovary cancer, gastric cancer, esophagus cancer, colonic cancer, or sarcoma. 4. The method of claim 1, wherein the anti-cancer drug is selected from the group consisting of: doxorubicin; Vincristine; paclitaxel; Cisplatin; Actinomycin; Bleomycin; Busulfan; Capecitabine; Carboplatin; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etop1; Vepeside; Etoposide; Fludarabine; Fluorouracil; Gemcitabine; Trastuzumab; Hydroxycarbamide; Idarubicin; Ifosfamide; Irinotecan; Lomustine; Melphalan; Mercaptopurine; Methotrexate; Mitomycin; Mitoxantrone; Dihydroxyanthraquinone; Oxaliplatin; Procarbazine; Methylhydrazine; rituximab; Steroid; Streptozocin; Docetaxel; Thioguanine; Thiotepa; Ledertepa; Tespamin; Raltitrexed; Topotecan; Treosulfan; Uracil; Vinblastine; Vinca alkaloid; Vindesine; Vinorelbine; and Hydroxycamptothecin. 5. The method of claim 1, wherein the at least one phthalide compound is ##STR00019##

Details for Patent 8,445,532

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26